Description: Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.
Home Page: www.handok.co.kr
132 Teheran-ro
Seoul,
06235
South Korea
Phone:
82 2 527 5114
Officers
| Name | Title |
|---|---|
| Mr. Young-Jin Kim M.B.A. | Chairman & CEO |
| Ms. Jeong-yol Cho | Pres |
| Min-Bok Lee | Managing Director |
| Byung-Chul Lee | Assistance Managing Director |
| Jin-Gi Baek | Sr. Managing Director |
| Shin-Gu Yeo | Sr. Managing Director |
| Jin Ki Baek | VP & Exec. Director |
| Doo-Seop Kim | Exec. Officer |
Exchange: KO
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6149 |
| Price-to-Sales TTM: | 0.4286 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |